Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)

被引：16

作者：

Maeda, Haruka ^{[1
,2
]}

Saito, Nobuo ^{[3
]}

Igarashi, Ataru ^{[4
,5
]}

Ishida, Masayuki ^{[6
]}

Suami, Kazuya ^{[7
]}

Yagiuchi, Ai ^{[7
]}

Kimura, Yuya ^{[8
]}

Komino, Masaru ^{[8
]}

Arai, Hiromi ^{[8
]}

Morikawa, Toru ^{[9
]}

Motohashi, Iori ^{[10
]}

Miyazawa, Rei ^{[10
]}

Moriyama, Tetsu ^{[11
]}

Kamura, Hiroshi ^{[12
]}

Terada, Mayumi ^{[13
]}

Kuwamitsu, Osamu ^{[14
]}

Hayakawa, Tomoichiro ^{[15
]}

Sando, Eiichiro ^{[16
,17
]}

Ohara, Yasuji ^{[18
]}

Teshigahara, Osamu ^{[19
]}

Suzuki, Motoi ^{[20
]}

Morimoto, Konosuke ^{[1
]}

机构：

[1] Nagasaki Univ, Inst Trop Med, Dept Resp Infect, 1-12-4 Sakamoto, Nagasaki 8528523, Japan

[2] Nagasaki Univ, Dept Clin Trop Med, Grad Sch Biomed Sci, Nagasaki, Japan

[3] Oita Univ, Fac Med, Dept Microbiol, Oita, Japan

[4] Yokohama City Univ, Unit Publ Hlth & Prevent Med, Sch Med, Yokohama, Kanagawa, Japan

[5] Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Econ & Outcomes Res, Tokyo, Japan

[6] Chikamori Hosp, Kochi, Japan

[7] Nagoya Ekisaikai Hosp, Nagoya, Aichi, Japan

[8] Saiseikai Kurihashi Hosp, Saitama, Japan

[9] Nara City Hosp, Nara, Japan

[10] Kawasaki Municipal Tama Hosp, Kawasaki, Kanagawa, Japan

[11] Moriyama Mem Hosp, Tokyo, Japan

[12] Loco Clin Nakameguro, Tokyo, Japan

[13] Nijigaoka Hosp, Nagasaki, Japan

[14] Gohongi Clin, Tokyo, Japan

[15] Hayakawa Internal Med Clin, Fukuoka, Japan

[16] Kita Fukushima Med Ctr, Fukushima, Japan

[17] Fukushima Med Univ, Fukushima, Japan

[18] Takagi Hosp, Nagoya, Aichi, Japan

[19] Mizuho St Clin, Nagoya, Aichi, Japan

[20] Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Tokyo, Japan

来源：

CLINICAL INFECTIOUS DISEASES | 2022年 / 75卷 / 11期

关键词：

SARS-CoV-2; COVID-19; vaccine effectiveness; Delta; Japan;

D O I：

10.1093/cid/ciac292

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

This multicenter test-negative case-control study showed messenger RNA COVID-19 vaccine effectiveness against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in Japan during July-September 2021: 88.7% among people aged 16-64 years and 90.3% among those aged >= 65 years. Background Although high vaccine effectiveness of messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines has been reported in studies in several countries, data are limited from Asian countries, especially against the Delta (B.1.617.2) variant. Methods We conducted a multicenter test-negative case-control study in patients aged >= 16 years visiting hospitals or clinics with signs or symptoms consistent with COVID-19 from 1 July to 30 September 2021, when the Delta variant was dominant (>= 90% of SARS-CoV-2 infections) nationwide in Japan. Vaccine effectiveness of BNT162b2 or mRNA-1273 against symptomatic SARS-CoV-2 infections was evaluated. Waning immunity among patients aged 16-64 years was also assessed. Results We enrolled 1936 patients, including 396 test-positive cases and 1540 test-negative controls for SARS-CoV-2. The median age was 49 years, 53.4% were male, and 34.0% had underlying medical conditions. Full vaccination (receiving 2 doses >= 14 days before symptom onset) was received by 6.6% of cases and 38.8% of controls. Vaccine effectiveness of full vaccination against symptomatic SARS-CoV-2 infections was 88.7% (95% confidence interval [CI], 78.8%-93.9%) among patients aged 16-64 years and 90.3% (95% CI, 73.6%-96.4%) among patients aged >= 65 years. Among patients aged 16-64 years, vaccine effectiveness was 91.8% (95% CI, 80.3%-96.6%) within 1-3 months after full vaccination, and 86.4% (95% CI, 56.9%-95.7%) within 4-6 months. Conclusions mRNA COVID-19 vaccines had high effectiveness against symptomatic SARS-CoV-2 infections in Japan during July-September 2021, when the Delta variant was dominant nationwide.

引用

页码：1971 / 1979

页数：9

共 50 条

[31] A case control study to assess effectiveness of measles containing vaccines in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children
Gujar, Nilesh
Tambe, Muralidhar
Parande, Malangori
Salunke, Nandkumar
Jagdale, Ganesh
Anderson, Sarah G.
Dharmadhikari, Abhijeet
Lakhkar, Anand
Kulkarni, Prasad S.
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (10) : 3316 - 3321
[32] Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination and Pediatric Age on Delta Variant Household Transmission
Ng, Oon Tek
Koh, Vanessa
Chiew, Calvin J.
Marimuthu, Kalisvar
Thevasagayam, Natascha May
Mak, Tze Minn
Chua, Joon Kiat
Ong, Shannen Si Hui
Lim, Yong Kai
Ferdous, Zannatul
Johari, Alifa Khairunnisa bte
Cui, Lin
Lin, Raymond Tzer Pin
Tan, Kelvin Bryan
Cook, Alex R.
Leo, Yee-Sin
Lee, Vernon J. M.
CLINICAL INFECTIOUS DISEASES, 2022, 75 (01) : E35 - E43
[33] Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Jiang, Chuanhao
Wang, Yali
Hu, Min
Wen, Lingjun
Wen, Chuan
Wang, Yang
Zhu, Weihong
Tai, Shi
Jiang, Zhongbiao
Xiao, Kui
Faria, Nuno Rodrigues
De Clercq, Erik
Xu, Junmei
Li, Guangdi
CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2020, 9 (09)
[34] Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Associated Urogenital Disease: A Current Update
Chu, Guangdi
Jiao, Wei
Xie, Fei
Zhang, Mingxin
Niu, Haitao
WORLD JOURNAL OF MENS HEALTH, 2021, 39 (03) : 444 - 453
[35] Real-World Effectiveness of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in Preventing Confirmed Infection in Patients on Chronic Hemodialysis
Butt, Adeel A.
Talisa, Victor B.
Yan, Peng
Shaikh, Obaid S.
Omer, Saad B.
Mayr, Florian B.
CLINICAL INFECTIOUS DISEASES, 2022, 75 (01) : E617 - E622
[36] A Possible Case of Vertical Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a Newborn With Positive Placental In Situ Hybridization of SARS-CoV-2 RNA
Alamar, Ihab
Abu-Arja, Mohammad H.
Heyman, Taryn
Roberts, Drucilla J.
Desai, Niyati
Narula, Pramod
Dygulska, Beata
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2020, 9 (05) : 636 - 639
[37] Mental health consequences of infections by coronaviruses including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Khan, Suliman
Siddique, Rabeea
Xiaoyan, Wang
Zhang, Ruiyi
Nabi, Ghulam
Afzal, Muhammad Sohail
Liu, Jianbo
Xue, Mengzhou
BRAIN AND BEHAVIOR, 2021, 11 (02):
[38] Is There an Association Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Streptococcus pneumoniae?
Howard, Leigh M.
CLINICAL INFECTIOUS DISEASES, 2021, 72 (05) : E76 - E78
[39] Emerging Biosensors to Detect Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Review
Lim, Wei Yin
Lan, Boon Leong
Ramakrishnan, Narayanan
BIOSENSORS-BASEL, 2021, 11 (11):
[40] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and glial cells: Insights and perspectives
Vargas, Gabriele
Geraldo, Luiz Henrique Medeiros
Salomao, Natalia Gedeao
Paes, Marciano Viana
Lima, Flavia Regina Souza
Gomes, Flavia Carvalho Alcantara
BRAIN BEHAVIOR & IMMUNITY-HEALTH, 2020, 7

← 1 2 3 4 5 →